DETOUR Resources - Endologix

Explore and dive into the
DETOUR System resources.

PTAB with the DETOUR System Launch Video

PTAB with the DETOUR System Launch Video
MM2663-US Rev 02

DETOUR System Procedural Animation

DETOUR System Procedural Animation
MM2589-US Rev 03

Podcast – Treating Complex PAD via Percutaneous Transmural Arterial Bypass

Podcast – Treating Complex PAD via Percutaneous Transmural Arterial Bypass
MM2727-US Rev 01

Webinar – Discussion with the Authors of Published Article about PTAB

Webinar – Discussion with the Authors of Published Article about PTAB
MM2733-US Rev 01

Revascularizing Complex SFA Lesions and CTOs: Is it PTAB with the DETOUR System Time?

Revascularizing Complex SFA Lesions and CTOs: Is it PTAB with the DETOUR System Time?
MM2716-US Rev 01

DETOUR System Brochure

DETOUR System Brochure
MM2655-US Rev 02

DETOUR System Patient Brochure

DETOUR System Patient Brochure
MM2658-US Rev 02

DETOUR System Patient Brochure (Spanish Translation)

DETOUR System Patient Brochure (Spanish Translation)
MM2658-US-ES-XL Rev 01

DETOUR System Coding Guide

DETOUR System Coding Guide
MM2710-US Rev 03

Reimbursement Frequently Asked Questions

Reimbursement Frequently Asked Questions
MM2709-US Rev 02

New Technology Add-on Payment Overview

New Technology Add-on Payment Overview
MM2734-US Rev 01

Legal Information:

INDICATIONS FOR USE:
The DETOUR™ System is indicated for use for percutaneous revascularization in patients with symptomatic femoropopliteal lesions from 200mm to 460mm in length with chronic total occlusions (100mm to 425mm) or diffuse stenosis >70% who may be considered suboptimal candidates for surgical or alternative endovascular treatments. The DETOUR™ System, or any of its components, is not for use in the coronary and cerebral vasculature.

CONTRAINDICATIONS:
The DETOUR™ System is contraindicated in patients with:

A distal common femoral artery (CFA) <7 mm in diameter.
Increased risk of deep vein thrombosis (DVT), such as patients with a recent history of DVT, thrombophilia, and disseminated malignancy.
Untreated flow-limiting aortoiliac occlusive disease.
Lack of patent single vessel tibial runoff to ankle.
Known coagulopathy, bleeding diathesis, or thrombocytopenia that cannot be medically managed.
Known hypersensitivities, allergies or contraindications to: Nitinol; PTFE; aspirin; heparin; antiplatelet; anticoagulant or thrombolytic therapy; or contrast media that cannot otherwise be medically managed.

Refer to Instructions for Use for more information concerning Indications, Contraindications, Specific Anatomic Considerations, Warnings, Precautions, and Adverse Events.

CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician.

NOTE: Not all product components are available in every country.

Please consult with your Endologix representative to confirm product availability.

Endologix^® is a registered trademark of Endologix LLC in the United States, Europe and Japan. All other trademarks are the property of their respective owners.

PTAB with the DETOUR System Launch Video MM2663-US Rev 02

DETOUR System Procedural Animation MM2589-US Rev 03

Podcast – Treating Complex PAD via Percutaneous Transmural Arterial Bypass MM2727-US Rev 01

Webinar – Discussion with the Authors of Published Article about PTAB MM2733-US Rev 01

Revascularizing Complex SFA Lesions and CTOs: Is it PTAB with the DETOUR System Time? MM2716-US Rev 01

DETOUR System Brochure MM2655-US Rev 02

DETOUR System Patient Brochure MM2658-US Rev 02

DETOUR System Patient Brochure (Spanish Translation) MM2658-US-ES-XL Rev 01

DETOUR System Coding Guide MM2710-US Rev 03

Reimbursement Frequently Asked Questions MM2709-US Rev 02

New Technology Add-on Payment Overview MM2734-US Rev 01